CHMCHIMERIC THERAPEUTICS LIMITEDMarket sensitive

CHM CORE-NK Phase 1B clinical trial achieves 60% CR/CRi

Date and time
Announcement type
Company Update

More from Health Care

More News

VR8Company Update5 October 2026

Vanadium Resources (ASX: VR8) Maps US$842m V-Iron Case